Cancellous Bone Implant Loosening Osteogenic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancellous bone implants often contain blood cells that can limit the viability and effectiveness of osteogenic cells, hindering bone formation and regeneration in treatments for various bone diseases and injuries.
Innovation Solution
Treatment of cancellous bone with loosening agents like collagenase or digestive enzymes to loosen osteogenic cells within the bone matrix, making them more available for osteogenic functions without releasing them, combined with antibiotic and antimycotic treatments to ensure bioburden reduction and preservation in suitable mediums for storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancellous bone implants are used to treat bone diseases and injuries, then bone formation and regeneration can be achieved, but the presence of blood cells in the implant limits the viability and effectiveness of osteogenic cells
Solution Approach 1:
The patent applies the extraction principle by removing blood cells from the cancellous bone implant through a washing process. The bone implant is washed with a washing solution to eliminate blood cells while preserving the osteogenic cells within the bone matrix, thereby eliminating the harmful effect of blood cells on osteogenic cell viability and effectiveness.
2Productivity
If loosening agents like collagenase are used to loosen osteogenic cells in the bone matrix, then osteogenic cells become more available for osteogenic functions, but the treatment process becomes more complex
Solution Approach 1:
The patent applies preliminary action by treating the cancellous bone with loosening agents such as collagenase or digestive enzymes before implantation. This pre-treatment loosens the osteogenic cells within the bone matrix, making them more available for osteogenic functions during the implantation and subsequent bone formation process, without requiring additional complex procedures during surgery.
3Reliability
If antibiotic and antimycotic treatments are applied to reduce bioburden, then implant safety is improved, but the treatment time and process complexity increase
Solution Approach 1:
The patent applies preliminary action by incorporating antibiotic and antimycotic treatments into the pre-implantation processing sequence. The cancellous bone is treated with antibiotics and antimycotics to reduce bioburden before implantation, ensuring implant safety while completing all necessary treatments during the preparation phase rather than extending treatment time into the surgical procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances bone formation rates and improves implant efficacy by maintaining viable osteogenic cells, allowing for effective bone regeneration and treatment of conditions such as avascular osteonecrosis, fractures, and bone fusions, while maintaining cell viability during storage.
Implementation Method 1
treated with at least one loosening agent, such as collagenase and/or a digestive enzyme, in order to loosen osteogenic cells in the bone matrix
Data Source
AI summary
A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation.